Study guide

5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites

ARRT Radiation Therapy Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Patient Care & Education

1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation

2 Chapter 2: Radiation Physics, Radiobiology & Protection

2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients

3 Chapter 5: Treatment Sites, Tumors & Classification

5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems

4 Chapter 3: Treatment Planning & Dosimetry

3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances

5 Chapter 4: Treatment Delivery, Image Guidance & QA

4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation

5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites

Key Takeaways Explain This Topic AI

The prostate's peripheral zone accounts for most cancers; PSA and Gleason/Grade Group drive risk stratification and treatment intensity.

Locally advanced cervical cancer requires definitive chemoradiation plus an intracavitary brachytherapy boost — brachytherapy is essential, not optional, for curative central pelvic dose.

Endometrial cancer is managed with surgery first; adjuvant radiation (often vaginal cuff brachytherapy alone) is reserved for higher-risk pathologic features.

Vulvar cancer drains to inguinofemoral nodes, requiring elective groin coverage even in early-stage disease.

Testicular lymphatic drainage goes to para-aortic (retroperitoneal) nodes because of the testis's embryologic retroperitoneal origin, not to inguinal nodes.

Last updated: July 2026

Prostate Cancer

The prostate surrounds the proximal urethra just below the bladder neck and is divided into three glandular zones on imaging and pathology:

  • Zone % of gland volume Clinical relevance
  • Peripheral zone ~70% Site of ~70–80% of prostate cancers; palpable on digital rectal exam
  • Transition zone ~25% Site of benign prostatic hyperplasia (BPH); minority of cancers
  • Central zone ~5% Uncommon site of malignancy

Key diagnostic and prognostic tools:

PSA (prostate-specific antigen) — a serum glycoprotein used for screening, risk stratification, and post-treatment monitoring; rising PSA after treatment (biochemical recurrence) can precede clinically detectable disease by months to years.

Gleason score / Grade Group — histologic grading based on the two most prevalent glandular patterns (each scored 1–5, summed to a Gleason score 6–10); higher scores indicate less differentiated, more aggressive disease. Grade Group 1 (Gleason ≤6) is low risk; Grade Group 5 (Gleason 9–10) is high risk.

Risk stratification combines PSA, Gleason/Grade Group, and clinical T-stage (NCCN low/intermediate/high risk) to guide treatment intensity — active surveillance for low-risk disease up to dose-escalated external beam radiation with androgen deprivation therapy (ADT) for high-risk disease.

Anatomic relationships drive planning constraints: the rectum lies immediately posterior (limiting posterior dose), the bladder sits superior/anterior, and the penile bulb/neurovascular bundles are considered for late toxicity. Rectal and bladder filling protocols (e.g., empty rectum, comfortably full bladder) reduce organ motion and improve day-to-day setup reproducibility.

Low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy is used alone for favorable-risk disease or as a boost combined with external beam radiation for intermediate/high-risk disease, exploiting the prostate's compact, accessible geometry for interstitial implantation.

Cervical Cancer

The cervix is the lower, narrow portion of the uterus connecting to the vagina. Cervical cancer is overwhelmingly associated with persistent high-risk HPV infection (types 16 and 18 most common), and most cases are SCC (with adenocarcinoma as the next most common histology).

FIGO staging for cervical cancer is based on clinical and imaging assessment of local extent (parametrial/vaginal involvement), nodal status, and distant spread, and is central to selecting treatment.

Early-stage, small tumors may be managed surgically; locally advanced cervical cancer (bulky Stage IB3 and above) is treated with definitive chemoradiation — external beam radiation to the pelvis (and, when involved, para-aortic nodes) with concurrent weekly cisplatin, followed by an intracavitary brachytherapy boost .

Brachytherapy is essential, not optional, in curative cervical cancer treatment: it delivers a highly conformal dose boost to the cervix and central pelvis that external beam alone cannot safely achieve, and omitting it is associated with significantly worse local control and survival.

Lymphatic drainage proceeds from parametrial nodes to external/internal iliac and obturator nodes , then to common iliac and para-aortic nodes — the rationale for extended-field radiation when pelvic or para-aortic nodes are involved.